Robert Malenka
Patrimonio netto: 5 M $ in data 31/08/2026
Patrimonio netto: 5 M $ in data 31/08/2026
Robert Malenka was the founder of MapLight Therapeutics, Inc., founded in 2018, where the title held was Director from 2018 to 2026.
Current jobs include Deputy Director at Wu Tsai Neurosciences Institute and Member at the National Academy of Medicine (United States).
Former job includes Professor at the University of California from 1996 to 1999.
Education includes a doctorate from Stanford University School of Medicine conferred in 1983.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 15/04/2026 | 348.138 ( 0,66% ) | 5 M $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services Operates as a professional membership organization | Corporate Officer/Principal | - |
| Società | Posizione | Fine |
|---|---|---|
| MAPLIGHT THERAPEUTICS, INC. | Fondatore | 23/06/2026 |
University of California
University of California Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/1999 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services Operates as a professional membership organization | Commercial Services |
University of California
University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stanford University School of Medicine
Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for debilitating central nervous system disorders | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale